Latest News

Tomivosertib Development in Frontline NSCLC Is Terminated
Tomivosertib Development in Frontline NSCLC Is Terminated

May 20th 2024

Topline findings from the KICKSTART study showed that tomivosertib led to modest activity in non-small cell lung cancer (NSCLC).

Emerging Biomarkers and Tumor Heterogeneity Lead the Way in Lung Cancer
Emerging Biomarkers and Tumor Heterogeneity Lead the Way in Lung Cancer

May 19th 2024

NVL-655 Earns FDA Breakthrough Therapy Designation in ALK-Positive NSCLC
NVL-655 Earns FDA Breakthrough Therapy Designation in ALK-Positive NSCLC

May 17th 2024

Phase 3 CheckMate -73L of Nivolumab/Ipilimumab in NSCLC Misses PFS End Point
Phase 3 CheckMate -73L of Nivolumab/Ipilimumab in NSCLC Misses PFS End Point

May 13th 2024

Intracranial Response Data Supports Use of Brigatinib in ALK+ NSCLC
Intracranial Response Data Supports Use of Brigatinib in ALK+ NSCLC

April 26th 2024

More News